| Market Capitalization (Millions $) |
1,052 |
| Shares
Outstanding (Millions) |
70 |
| Employees |
196 |
| Revenues (TTM) (Millions $) |
92 |
| Net Income (TTM) (Millions $) |
-179 |
| Cash Flow (TTM) (Millions $) |
-5 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
4D Molecular Therapeutics Inc is a biotechnology company that focuses on developing gene therapies for the treatment of serious genetic diseases. The company utilizes an innovative approach called targeted gene therapy, which involves delivering therapeutic genes directly to specific cells in the body. This approach has the potential to provide more effective and precise treatments for a wide range of genetic disorders.
4D Molecular Therapeutics Inc has developed a proprietary Adeno-Associated Virus (AAV) vector platform that enables the targeted delivery of therapeutic genes to specific organs, tissues, and cell types. This platform allows for precise control over the delivery and expression of therapeutic genes, minimizing the risk of off-target effects and enhancing the efficacy of the treatment.
The company is actively involved in preclinical and clinical studies to evaluate the safety and effectiveness of their gene therapies. They are working on developing treatments for diseases such as cystic fibrosis, Duchenne muscular dystrophy, and Fabry disease.
4D Molecular Therapeutics Inc collaborates with leading academic institutions, biopharmaceutical companies, and patient advocacy groups to accelerate the development of their gene therapies. They are committed to advancing the field of gene therapy and improving the lives of patients suffering from genetic diseases.
Company Address: 5858 Horton Street #455 Emeryville 94608 CA
Company Phone Number: 505-2680 Stock Exchange / Ticker: NASDAQ FDMT
|
6.09% 
175.83 %